{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:11:37Z","timestamp":1776395497926,"version":"3.51.2"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.sxmr.2018.09.007","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T07:42:31Z","timestamp":1543563751000},"page":"329-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Review of Management Options for Active-Phase Peyronie\u2019s Disease"],"prefix":"10.1093","volume":"7","author":[{"given":"Scott C.","family":"Brimley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faysal A.","family":"Yafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang Minh","family":"Tue Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Hatzichristodoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2018.09.007_bib1","first-page":"230","article-title":"Standard operating procedures for Peyronie\u2019s disease","volume":"10","author":"Levine","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib2","first-page":"2350","article-title":"Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib3","first-page":"302","article-title":"Peyronie's disease in teenagers","volume":"9","author":"Tal","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib4","first-page":"905","article-title":"Evidence-based management guidelines on Peyronie\u2019s disease","volume":"13","author":"Chung","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib5","series-title":"Urology at a glance","first-page":"225","article-title":"Peyronie's disease","author":"Hatzichristodoulou","year":"2014"},{"key":"10.1016\/j.sxmr.2018.09.007_bib6","doi-asserted-by":"crossref","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: A population-based study","volume":"11","author":"Stuntz","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.sxmr.2018.09.007_bib7","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"A\u00a0population-based study of Peyronie's disease: Prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.ijir.3900875","article-title":"Pathophysiology of Peyronie's disease","volume":"14","author":"Moreland","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib9","first-page":"186","article-title":"Trauma as the cause of Peyronie's disease: Penile fracture as a model of trauma","volume":"172","author":"Zargooshi","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.sxmr.2015.10.002","article-title":"The genetic basis of Peyronie disease: A review","volume":"4","author":"Herati","year":"2016","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2018.09.007_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrurol.2010.233","article-title":"Current status of the surgical management of Peyronie's disease","volume":"8","author":"Kadioglu","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijir.2011.45","article-title":"Review of non-surgical treatment options for Peyronie's disease","volume":"24","author":"Larsen","year":"2012","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib13","first-page":"653","article-title":"Psychological impact of Peyronie's disease: A review","volume":"10","author":"Nelson","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib14","first-page":"2359","article-title":"The management of Peyronie's disease: Evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ijir.2008.30","article-title":"A\u00a0critical appraisal of current diagnosis and treatment","volume":"20","author":"Smith","year":"2008","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ijir.2011.24","article-title":"Relationship between penile fracture and Peyronie's disease: A prospective study","volume":"23","author":"Acikgoz","year":"2011","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00120-015-3796-1","article-title":"Conservative therapy of Peyronie' s disease: Update 2015","volume":"54","author":"Hatzichristodoulou","year":"2015","journal-title":"Urologe A"},{"key":"10.1016\/j.sxmr.2018.09.007_bib18","first-page":"2115","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib19","first-page":"745","article-title":"Peyronie\u2019s disease: AUA Guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ijir.2013.7","article-title":"Surgical therapy of Peyronie's disease by partial plaque excision and grafting with collagen fleece: Feasibility study of a new technique","volume":"25","author":"Hatzichristodoulou","year":"2013","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.21037\/tau.2017.07.17","article-title":"Peyronie\u2019s graft surgery\u2014Tips and tricks from the masters in andrologic surgery","volume":"6","author":"Hatzichristodoulou","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib22","first-page":"416","article-title":"The PICS technique: A novel approach for residual curvature correction during penile prosthesis implantation in patients with severe Peyronie\u2019s disease using the collagen fleece TachoSil","volume":"15","author":"Hatzichristodoulou","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib23","first-page":"3121","article-title":"Peyronie's disease plaque calcification\u2014Prevalence, time to identification, and development of a new grading classification","volume":"10","author":"Levine","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","article-title":"l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures","volume":"9","author":"Valente","year":"2003","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.sxmr.2018.09.007_bib25","first-page":"1472","article-title":"The role of PDE5 inhibitors in penile septal scar remodeling: Assessment of clinical and radiological outcomes","volume":"8","author":"Chung","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction","volume":"183","author":"Ozturk","year":"2014","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.sxmr.2018.09.007_bib27","first-page":"954","article-title":"Urologist practice patterns in the management of peyronie's disease: A nationwide survey","volume":"5","author":"Shindel","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","article-title":"Mechanisms of disease: New insights into the cellular and molecular pathology of peyronie's disease","volume":"2","author":"Gonzalez-Cadavid","year":"2005","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib29","first-page":"1398","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: A double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.sxmr.2018.09.007_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1442-2042.2006.01270.x","article-title":"Outcome analysis for conservative management of Peyronie's disease","volume":"13","author":"Kohei","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E in the conservative treatment of peyronie's disease: Legend or\u00a0reality? A controlled study of 70 cases","volume":"1","author":"Paulis","year":"2012","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2018.09.007_bib32","first-page":"129","article-title":"Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: Results of clinical application","volume":"9","author":"Paulis","year":"2017","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib33","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2018.09.007_bib34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","article-title":"A\u00a0double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie\u2019s disease","volume":"106","author":"Safarinejad","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.09.007_bib35","first-page":"1","article-title":"Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: A case-control study","volume":"8","author":"Paulis","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ijir.2010.20","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic peyronie's disease: A double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad","year":"2010","journal-title":"Int J Impotence Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.surneu.2005.10.023","article-title":"\u03c9-3 Fatty acids (fish oil) as an anti-inflammatory: An alternative to nonsteroidal anti-inflammatory drugs for discogenic pain","volume":"65","author":"Maroon","year":"2005","journal-title":"Surg Neurol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib38","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1517\/14656566.2011.544252","article-title":"Current status and new developments in Peyronie's disease: Medical, minimally invasive and surgical treatment options","volume":"12","author":"Gur","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.sxmr.2018.09.007_bib39","first-page":"192","article-title":"Pharmacological therapy in patients diagnosed with Peyronie's disease","volume":"5","author":"Halal","year":"2012","journal-title":"J\u00a0Med Life"},{"key":"10.1016\/j.sxmr.2018.09.007_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","article-title":"Is colchicine effective in Peyronie's disease? A pilot study","volume":"44","author":"Akkus","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.09.007_bib41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie's disease: A randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad","year":"2004","journal-title":"Int J Impotence Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","article-title":"Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease","volume":"91","author":"Prieto","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.09.007_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-l-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report","volume":"88","author":"Biagiotti","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.09.007_bib44","first-page":"770","article-title":"Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (potaba)","volume":"81","author":"Zarafonetis","year":"1959","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0022-4804(90)90197-A","article-title":"Calcium antagonists retard extracellular matrix production in connective tissue equivalent","volume":"49","author":"Lee","year":"1990","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib47","first-page":"2483","article-title":"Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea","volume":"168","author":"Martin","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib48","first-page":"477","article-title":"Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie\u2019s disease\u2014A placebo-controlled pilot study","volume":"4","author":"Fitch","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ijir.2015.22","article-title":"Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: A randomized, prospective, placebo-controlled pilot study","volume":"28","author":"Twidwell","year":"2015","journal-title":"Int J Impotence Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib50","first-page":"417","article-title":"Possibility of piezoelectric lithotripter use in the treatment of serious cavernous fibrosis","volume":"61","author":"Bellorofonte","year":"1989","journal-title":"Arch Ital Urol Nefrol Androl"},{"key":"10.1016\/j.sxmr.2018.09.007_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/089277903321196788","article-title":"Objective and subjective changes in patients with Peyronie's disease after management with shockwave therapy","volume":"17","author":"Michel","year":"2003","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib52","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.ijir.3901192","article-title":"Extracorporeal shockwave therapy for Peyronie's disease does not correct penile deformity","volume":"16","author":"Strebel","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib53","first-page":"296","article-title":"Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: Results of a prospective approach","volume":"171","author":"Hauck","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib54","first-page":"740","article-title":"Extracorporeal shock wave therapy for Peyronie's disease: Exploratory meta-analysis of clinical trials","volume":"171","author":"Hauck","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1159\/000020359","article-title":"Extracorporal shock wave therapy in the treatment of Peyronie's disease. First\u00a0results of a case-controlled approach","volume":"38","author":"Hauck","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib56","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","article-title":"Limited shock wave therapy vs sham treatment in men with Peyronie's disease: Results of a prospective randomized controlled double-blind trial","volume":"106","author":"Chitale","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.09.007_bib57","first-page":"2815","article-title":"Extracorporeal shock wave therapy in Peyronie's disease: Results of a placebo-controlled, prospective, randomized, single-blind study","volume":"10","author":"Hatzichristodoulou","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A\u00a0first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease","volume":"56","author":"Palmieri","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib59","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ucl.2011.02.006","article-title":"Review of nonsurgical treatment options","volume":"38","author":"Larsen","year":"2011","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.sxmr.2018.09.007_bib60","first-page":"2268","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib61","first-page":"704","article-title":"Is intralesional verapamil effective therapy for Peyronie\u2019s disease?","volume":"188","author":"Levine","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib62","first-page":"3","article-title":"Nonsurgical interventions for Peyronie's diease: 2011 update","volume":"33","author":"Schaeffer","year":"2012","journal-title":"J\u00a0Androl"},{"key":"10.1016\/j.sxmr.2018.09.007_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2010.04.004","article-title":"Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction","volume":"58","author":"Vardi","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib64","first-page":"1769","article-title":"Does low intensity extracorporeal shock wave therapy have a physiological effect\u00a0on erectile function? Short-term results of a randomized, double-blind, sham controlled study","volume":"187","author":"Vardi","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib65","doi-asserted-by":"crossref","first-page":"775","DOI":"10.4111\/kju.2015.56.11.775","article-title":"Peyronie\u2019s disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men","volume":"56","author":"Chung","year":"2015","journal-title":"Korean J Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib66","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4103\/0974-7796.192100","article-title":"Role of extracorporeal shock wave therapy in management of Peyronie\u2019s disease: A preliminary report","volume":"8","author":"Shimpi","year":"2016","journal-title":"Urol Ann"},{"key":"10.1016\/j.sxmr.2018.09.007_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-016-1834-2","article-title":"Extracorporeal shock wave therapy (ESWT) in urology: A systematic review of outcome in Peyronie's disease, erectile dysfunction and chronic pelvic pain","volume":"35","author":"Fojecki","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ijir.2016.24","article-title":"A\u00a0meta-analysis of extracorporeal shock wave therapy for Peyronie's disease","volume":"28","author":"Gao","year":"2016","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2018.09.007_bib69","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrurol.2017.119","article-title":"Low-intensity shockwave therapy for erectile dysfunction: Is the evidence strong enough?","volume":"14","author":"Fode","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib70","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib71","first-page":"1481","article-title":"Collagenase Clostridium histolyticum for the treatment of Peyronie's disease: The development of this novel pharmacologic approach","volume":"12","author":"Gelbard","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib72","first-page":"56","article-title":"Collagenase versus placebo in the treatment of Peyronie\u2019s disease: A double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib73","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJMoa0810866","article-title":"Injectable collagenase Clostridium histolyticum for Dupuytren's contracture","volume":"361","author":"Hurst","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-5347(17)47123-0","article-title":"The use of collagenase in the treatment of Peyronie\u2019s disease","volume":"134","author":"Gelbard","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib75","first-page":"2268","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib76","first-page":"199","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib77","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase Clostridium histolyticum: Safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.09.007_bib78","first-page":"1051","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie\u2019s disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib79","first-page":"1220","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of\u00a0acute-phase Peyronie\u2019s disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib80","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol","volume":"120","author":"Abdel","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.09.007_bib81","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/andr.12302","article-title":"Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie's disease","volume":"5","author":"Anaissie","year":"2017","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2018.09.007_bib82","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.esxm.2017.02.001","article-title":"Changes in the effects of Peyronie's disease after treatment with collagenase Clostridium histolyticum: Male patients and their female partners","volume":"5","author":"Goldstein","year":"2017","journal-title":"Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib83","first-page":"394","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon \u03b1-2b for minimally invasive treatment for Peyronie\u2019s disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib84","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: A randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.09.007_bib85","first-page":"1704","article-title":"Intralesional injection of interferon-\u03b12b improves penile curvature in men with Peyronie's disease independent of plaque location","volume":"194","author":"Stewart","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.09.007_bib86","first-page":"558","article-title":"Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study","volume":"6","author":"Gontero","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.09.007_bib87","first-page":"e746","article-title":"lba8 preliminary outcomes of a novel penile traction device (restorex) in men with Peyronie\u2019s disease: A randomized, controlled trial","volume":"199","author":"Ziegelmann","year":"2018","journal-title":"J\u00a0Urol"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052118301112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052118301112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:37:17Z","timestamp":1672774637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052118301112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2050052118301112"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.09.007","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Management Options for Active-Phase Peyronie\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}